U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H18N4O2
Molecular Weight 298.3403
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIRIBEDIL

SMILES

c1cnc(nc1)N2CCN(CC2)Cc3ccc4c(c3)OCO4

InChI

InChIKey=OQDPVLVUJFGPGQ-UHFFFAOYSA-N
InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2

HIDE SMILES / InChI
Piribedil is an antiparkinsonian agent which acts as D2 and D3 receptor agonist. In European countries and worldwide it is used as a monotherapy or in combination with dopatherapy for treatment of Parkinson's disease, cognitive impairment and obliterating arteriopathy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35462
Gene ID: 1814.0
Gene Symbol: DRD3
Target Organism: Homo sapiens (Human)
Target ID: P14416
Gene ID: 1813.0
Gene Symbol: DRD2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TRIVASTAL

Approved Use

Adjunctive treatment of intermittent claudication in chronic obliterating arteriopathies of the lower limbs (in stage 2).
Palliative
TRIVASTAL

Approved Use

Adjunctive symptomatic treatment of chronic pathological cognitive and neurosensorial deficit in elderly subjects (excluding Alzheimer's disease and other dementia).
Primary
TRIVASTAL

Approved Use

Treatment of Parkinson's disease: either as monotherapy (treatment of forms with predominant tremor), or in association with dopatherapy from the outset, or secondarily, particularly in forms with tremor.
PubMed

PubMed

TitleDatePubMed
Parkinsonism by haloperidol and piribedil.
1978 Oct 31
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
2001 Jun
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
2001 Mar
[Parkinson disease: diagnostic and therapeutic criteria].
2001 Mar 3
Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles.
2001 May-Jun
[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
2003
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
2003 Apr
Quantitative determination of some pharmaceutical piperazine derivatives through complexation with iron(III) chloride.
2003 Aug
Piribedil-induced sleep attacks in Parkinson's disease.
2003 Feb
Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study.
2003 Mar
[Treatment of Parkinson's disease: use of piribedil].
2004
Acute treatment of migraine. Breaking the paradigm of monotherapy.
2004 Jan 28
Determination of piribedil in pharmaceutical formulations by micellar electrokinetic capillary chromatography.
2004 May
[The role of pronoran in the therapy of late stage of Parkinson's disease].
2006
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
2006 Dec
Restless legs syndrome: diagnosis and review of management options.
2006 Jun
Activation of D2-like receptors induces sympathetic climactic-like responses in male and female anaesthetised rats.
2006 Jun
Enhancement in dissolution pattern of piribedil by molecular encapsulation with beta-cyclodextrin.
2006 Mar
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
2006 Nov
[Cognitive disturbances and dysfunction of neuromediator systems in cerebral vascular insufficiency after treatment with pronoran].
2007
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.
2007
Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency.
2007 Jan 30
[Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
2008
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.
2008 Sep
Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.
2009 Jun 10
Patents

Patents

Sample Use Guides

For the treatment of Parkinson's disease as a monotherapy, piribedil should be administered orally at 150 to 250 mg.
Route of Administration: Oral
Binding of piribedil to D2, D3 and D4 receptors was measured using [3H]spiperone as a radiolabel. Coronal sections from rat brains were cut at the level of the anterior caudate-putame. The sections were thaw-mounted on gelatin-coated glass slides. Sections were incubated for 5 min in a 50mM Tris-HCl buffer, then were incubated for 30 min at room temperature in the incubation buffer. Piribedil was tested in vitro at 5 different concentrations, from 10 uM to 1 nM.
Name Type Language
PIRIBEDIL
INN   MART.   MI   WHO-DD  
INN  
Official Name English
PIRIBEDIL [INN]
Common Name English
EU-4200
Code English
PIRIBEDIL [WHO-DD]
Common Name English
2-(4-PIPERONYL-1-PIPERAZINYL)PYRIMIDINE
Systematic Name English
TRIVASTAL
Brand Name English
ET-495
Code English
PIRIBEDIL [MI]
Common Name English
PIRIBEDIL [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC N04BC08
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
WHO-VATC QN04BC08
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
NCI_THESAURUS C66884
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
Code System Code Type Description
DRUG BANK
DB12478
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
MESH
D010891
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
RXCUI
8353
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY RxNorm
FDA UNII
DO22K1PRDJ
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
NCI_THESAURUS
C81082
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
MERCK INDEX
M8877
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
222-764-6
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
WIKIPEDIA
PIRIBEDIL
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
ChEMBL
CHEMBL1371770
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
CAS
3605-01-4
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
INN
2569
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
EPA CompTox
3605-01-4
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
PUBCHEM
4850
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
DRUG CENTRAL
2202
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
EVMPD
SUB09908MIG
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY